STARPHARMA HLDG.SP.ADR/10 Total Liabilities
STARPHARMA HLDG.SP.ADR/10 total liabilities. Based on the latest financial reports, STARPHARMA HLDG.SP.ADR/10 (PQ6A) has total liabilities worth €6.42 Million EUR (≈ $7.51 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See STARPHARMA HLDG.SP.ADR/10 liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of STARPHARMA HLDG.SP.ADR/10 (2022–2025)
Total liabilities of STARPHARMA HLDG.SP.ADR/10 from 2022 to 2025. This chart illustrates how STARPHARMA HLDG.SP.ADR/10's total liabilities have evolved over time, based on quarterly financial data.
STARPHARMA HLDG.SP.ADR/10 Competitors by Total Liabilities
The table below lists competitors of STARPHARMA HLDG.SP.ADR/10 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kervan Gıda Sanayi Ve Ticaret As
IS:KRVGD
|
Turkey | TL9.16 Billion |
|
CHINA NEW CITY COMM.
F:C7B
|
Germany | €8.38 Billion |
|
Nakamoto Inc.
NASDAQ:NAKA
|
USA | $186.10 Million |
|
HELIOS FAIRFAX PARTNERS
F:3UD
|
Germany | €95.85 Million |
|
Mobile Infrastructure Corporation
NASDAQ:BEEP
|
USA | $212.71 Million |
|
Galleon Gold Corp
V:GGO
|
Canada | CA$39.56 Million |
|
Han Chang Pape
KO:009460
|
Korea | ₩207.27 Billion |
|
Gyldendal ASA
OL:GYL
|
Norway | Nkr1.25 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down STARPHARMA HLDG.SP.ADR/10's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see STARPHARMA HLDG.SP.ADR/10 balance sheet assets.
Liquidity & Leverage Metrics
STARPHARMA HLDG.SP.ADR/10 Total Liabilities Ratios Explained
STARPHARMA HLDG.SP.ADR/10 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how STARPHARMA HLDG.SP.ADR/10's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for STARPHARMA HLDG.SP.ADR/10 (2022–2025)
The table below shows the annual total liabilities of STARPHARMA HLDG.SP.ADR/10 from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | €6.42 Million ≈ $7.51 Million |
-26.16% |
| 2024-06-30 | €8.70 Million ≈ $10.17 Million |
-49.64% |
| 2023-06-30 | €17.27 Million ≈ $20.19 Million |
-2.87% |
| 2022-06-30 | €17.78 Million ≈ $20.79 Million |
-- |
About STARPHARMA HLDG.SP.ADR/10
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company's products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurr… Read more